The Trump administration can slash $783 million of research funding in its push to cut federal diversity, equity and ...

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

On September 10, join this virtual event to hear industry-leading insights to improve operational efficiency and regulatory ...

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...

Soleno Therapeutics CEO responds to a 415-page short-seller report alleging safety issues tied to the company's newly ...

Neuroscientists have long held that the brain reorganizes itself when a body part is amputated. A new study says that’s not ...

The FDA's controversial rejection of a skin cancer therapy from Replimune Group has prompted Krystal Biotech to shut down of a clinical trial involving a similar drug.

This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without long-promised treatments.

The FDA has agreed to speed up a review of a rare disease drug developed by Stealth BioTherapeutics, a notable step after the company said it may have to close its doors otherwise.